No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study.

Aysegul AtmacaI DemirciC HaymanaI TasciI SahinE CakalN AtaS DagdelenS SalmanR EmralM SahinO CelikT DemirD ErtugrulU UnluturkM CaglayanI SatmanA Sonmez

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)

Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.

Keyphrases

coronavirus disease
sars cov
polycystic ovary syndrome
postmenopausal women
bone mineral density
pregnancy outcomes
emergency department
coronary artery disease
body composition
breast cancer risk
mechanical ventilation
adipose tissue
extracorporeal membrane oxygenation